(lp0
S'Better Buy: Celgene Corporation vs. Gilead Sciences Motley Fool - Mar 27, 2017 In the other corner stands Gilead Sciences, Inc. , an antiviral heavyweight that may be past its prime.'
p1
aS"Jonathan Jacobson's 4Q Investment Spotlight: Tesla Inc , Gilead Sciences ... Smarter Analyst - Mar 27, 2017 By examining 13F forms filed with the SEC we can see that in Q4 Jacobson boosted the fund's positions in controversial automaker Tesla Inc  and healthcare giant Gilead Sciences, Inc. . Jacobson himself has a traditionally&nbsp;...Gilead Sciences Inc. performed Poor with a change of -0.01% in the Last Trade - Free ObserverHighly Traded Stock: Gilead Sciences Inc.  - HugoPress"
p2
aS"The Best-Case Scenario for Gilead Sciences, Inc. Motley Fool - Mar 24, 2017 Gilead Sciences surprised many observers with a dismal outlook for hepatitis C virus  drug sales in 2017. The company hasn't been able to answer an all-important question: When will HCV sales stabilize? I don't know the answer to that question ...What to Expect from Gilead Sciences, Inc.  Amid M&amp;A Buzz and Upcoming ... - Smarter AnalystGilead defended at Jefferies - Seeking Alpha"
p3
aS'3 Numbers That Make Gilead Sciences, Inc. Look Cheaper Than It Really Is Motley Fool - Mar 16, 2017 Shares of Gilead Sciences  are trading at levels last seen in the first half of 2014, when trailing-12-month revenue and earnings were substantially lower than they are today.'
p4
aS"Here's Why the Best Is Yet to Come for Gilead Sciences, Inc. Motley Fool - Mar 7, 2017 Several of its most promising pipeline prospects are still years away from commercialization. All of these statements are true for Gilead Sciences . But is the big biotech destined for perpetual malaise? Not hardly. Here's why the best is ...Barclays Analyst Pens Open Letter To Gilead Board And Management - BenzingaBuy or Sell? What Analysts Recommends: Gilead Sciences Inc. , The Dow ... - StockNewsJournal"
p5
aS"Better Buy: Biogen Inc. vs. Gilead Sciences Inc. Motley Fool - Feb 27, 2017 The two stocks do already compete in a sense, though, for investors' affections. That's a battle where Biogen has come out on top over the last year.Gilead Sciences Is Heading To $57 - Seeking AlphaGilead Sciences to Present at the Barclays Global Healthcare Conference on ... - Yahoo Finance"
p6
aS"I don't think Gilead offers a compelling risk/reward, despite the stock is ... Seeking Alpha - Mar 23, 2017 Thus, in this article, I will focus on a quantitative valuation of the company using a DCF analysis and without taking into account any potential M&amp;A that Gilead could announce in 2017, which looks unpredictable, to assess if the market has already ..."
p7
aS'Gilead Sciences, Inc.  Ex-Dividend Date Scheduled for March 14, 2017 Nasdaq - Mar 13, 2017 Gilead Sciences, Inc.  will begin trading ex-dividend on March 14, 2017. A cash dividend payment of $0.52 per share is scheduled to be paid on March 30, 2017.3 M&amp;A Scenarios For Gilead Sciences - Seeking AlphaIs It Time to Sell Gilead Sciences ? - Smarter Analyst'
p8
aS"Gilead: Milligan's Response Seeking Alpha - Mar 21, 2017 The session featured Barclays' senior biotech analyst, Geoff Meacham, who had recently butted to the top tier of the &quot;Gilead  must act&quot; chorus. Now he was kicking off his company's vaunted global healthcare conference with a one-on-one&nbsp;..."
p9
aS"Can We Learn Anything From The Technical Chart of Gilead Sciences, Inc. ? NY Stock News - 14 hours ago Gilead Sciences, Inc.  has presented a rich pool of technical data in recent sessions. These are the trends we've been tracking and how we feel they should be played in the current environment."
p10
a.